



Published in final edited form as:

*J Epidemiol Community Health*. 2010 July ; 64(7): 587–590. doi:10.1136/jech.2009.090472.

## The Environmental Epidemiology of Atrial Arrhythmogenesis: A Research Agenda

Eric A. Whitsel<sup>1,2</sup> and Christy L. Avery<sup>1</sup>

<sup>1</sup>University of North Carolina, Gillings School of Global Public Health, Department of Epidemiology, Chapel Hill, NC, USA

<sup>2</sup>University of North Carolina, School of Medicine, Department of Medicine, Chapel Hill, NC, USA

### Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in clinical practice and as a potent risk factor for heart failure and stroke, it makes an important contribution to cardiovascular disease (CVD) and all-cause mortality. Its large and increasing population burden has prompted a recent shift in the focus of AF research, from that concentrating on its treatments and complications, to the evaluation of its putative risk factors including ambient air pollution, the topic of this review. Although the review pertains specifically to AF, much of its content is drawn from and therefore applicable to the study of other arrhythmias, the conduct of which is confronted by many of the same challenges. Meeting these challenges involves recognizing the collective importance of 1) large, ethnically and geographically diverse, clinically well-characterized populations; 2) methods for reducing uncertainty in outcome ascertainment, distinguishing effects of pervasive environmental exposures, and improving their estimation; 3) approaches to evaluation of susceptibility; as well as 4) strategies for informing regulatory policies designed to help control population-level risks for CVD.

### Keywords

Air Pollution; Epidemiology; Electrocardiography; Arrhythmia; Atrial Fibrillation

### State of the Science

Atrial fibrillation is a common cardiac arrhythmia in which disorganized electrical impulses in the atria or pulmonary veins overwhelm those in the sinoatrial node, leading to chaotic and continuous electrical activity of the atria, loss of rate control, and an irregularly irregular pulse. Available estimates suggest that approximately four percent of U.S. adults aged sixty

---

**License Statement:** The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in JECH editions and any other BMJPL products to exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

Correspondence: Eric A. Whitsel, University of North Carolina - Chapel Hill, Departments of Epidemiology and Medicine, Cardiovascular Disease Program, Bank of America Center, Suite 306-E, 137 East Franklin Street, Chapel Hill, NC 27514, (T) 919-966-3168 or 1967, (F) 919-966-9800, ewhitsel@email.unc.edu.

**Competing interests:** None declared

or more years have been diagnosed with this disease [1] and similar estimates have been reported in European populations [2, 3]. However, the prevalence of AF is likely to be much higher, reflecting the large proportion of cases that are either intermittent, asymptomatic, or undetected by the resting, supine, standard twelve-lead electrocardiogram (ECG), an insensitive clinical tool often used in initial attempts to diagnose it [4]. Despite being common, clinical and sub-clinical forms of AF are associated with reduced cardiac performance, functional status and quality of life. Moreover, the arrhythmia accounts for fifteen percent of ischemic strokes [5], is a potent risk factor for heart failure [6], and thereby contributes to both the burden of cardiovascular disease (CVD) and all-cause mortality [5].

The majority of AF research to date has focused on treatments for and complications of this disease [7]. Although several AF risk factors have been described (including age; male sex; race; family history[8, 9]; single nucleotide polymorphisms on chromosomes 1q21, 4q25 and 16q22 [7, 10-13]; myocardial infarction; valvular heart disease; hyperthyroidism; hypertension; diabetes; obesity; and smoking), AF prevention has been studied much less extensively despite projections suggesting that the prevalence will increase 2.5-fold by 2050 [1]. Indeed, the cumulative risk of incident AF at age 80 is 19% in whites and 11% in African-Americans, a paradox inconsistent with the relative preponderance of AF risk factors in the latter race group, but one also observed in other contexts [14]. Research focused on AF prevention, including the identification of modifiable, pervasive risk factors that have potential to help elucidate and eliminate these disparities, is therefore needed [7].

Ambient air pollution exposure is an established cardiovascular disease risk factor [15, 16] that may trigger AF paroxysms via direct and / or indirect effects on the atrial myocardium. Direct effects may be due to the actions on membrane ion currents of inhaled particles hematogenously translocated from the lungs to the atria and pulmonary veins [17-19]. Indeed, the chemical components of ambient particulate matter (PM) air pollution include noxious fossil fuel combustion species, as well as non-metallic and metallic cations capable of affecting how sodium, potassium, calcium, and magnesium are transported by channel proteins that maintain resting trans-membrane voltages critical to the generation and conduction of action potentials in the atrial myocardium [20]. Indirect effects may depend on autonomic, inflammatory and / or ischemic mechanisms [7]. Such initiating mechanisms may include 1) reflexive responses of the cardiac autonomic nervous system to particulate activation of chemosensitive pulmonary afferents; 2) stimulus-evoked production and release of inflammatory cytokines from pulmonary macrophages, epithelial cells, and fibroblasts; or 3) inhibition of endogenous fibrinolytic capacity, subclinical coronary thrombosis and ischemia, as suggested by experimental, clinical and epidemiologic evidence [21-26].

Although several studies have examined how mass concentrations of PM less than 2.5 and 10  $\mu\text{m}$  in aerodynamic diameter ( $\text{PM}_{2.5}$ ;  $\text{PM}_{10}$ ) affect atrial and ventricular arrhythmogenesis [16, 27-39], relatively few have done so in large, multi-city, racially diverse, gender-balanced populations without implantable cardioverter-defibrillators (ICDs) [40], and to our knowledge, none have evaluated the association between exposures to PM chemical components and AF or interval-scale, i.e. “continuous” ECG measures that have been associated with incident AF (PR interval; P wave duration, amplitude, area, terminal

force) [4]. It therefore remains unclear whether air pollution-AF associations observed in small, geographically homogeneous, majority-male, CVD-burdened convenience samples are generalizable to other populations. It also remains unclear how the associations vary by subpopulation characteristics. Moreover, how reliance on unvalidated arrhythmic causes of death, assignment of air pollution exposures with little consideration of exposure measurement error, and failure to assess effects of multiple co-pollutants influences the validity of extant inferences regarding air pollution-AF associations is unknown.

## A Research Agenda

Research addressing these criticisms is therefore a priority. Ancillary studies of previously well-characterized populations provide resource-efficient opportunities for such research, especially those that have or will be undertaking systematic collection of 24-48 hour Holter ECGs using standardized protocols or central adjudication of in- and outpatient AF by trained and certified physician reviewers. These strategies represent substantial improvements over ascertainment of AF using standard 10-second ECGs, unvalidated self-reports, hospital discharge diagnoses, and death certificates with no concomitant effort dedicated to distinguishing between AF as an immediate, contributing or underlying cause of heart failure and stroke deaths.

Although physician adjudication and Holter electrocardiography will improve AF ascertainment, others have argued that paroxysmal arrhythmias frequent enough to be captured by insensitive, but highly specific, short recordings may carry more prognostic significance than those so infrequent that they require long recordings to capture them [40]. In addition, potential for bias in air pollution-AF associations related to diagnostic insensitivity will not be completely eliminated by longer ECG recordings. Several forms of exposure measurement error—one of which is associated with the use of geocoded residential addresses—may well compound such biases. Indeed, the ability to reliably and accurately link residential addresses with spatial coordinates and statistical tabulation areas using geographic information systems software may be critically important because geocoding error has the potential to distort downstream interpolation of residence-specific ambient pollution exposures and definition of socioeconomic contexts within which pollution exposures occur. These distortions may, in turn, lead to biased estimates of association and contextual effect modification [41, 42].

An additional, and in this setting, arguably more important form of exposure measurement error is related to the use of ambient concentrations as surrogates for personal exposure. The potential importance of this uncertainty is underscored by evidence of the so-called “personal cloud”; findings that ambient, residential-outdoor, and personal PM exposures appear to be more weakly correlated than originally suspected; and that characteristics of participants, studies and the environments in which they are conducted may affect the accuracy of this proxy [43-45]. Use of spatially interpolated, residence-specific ambient pollution concentrations as proxies for monitored exposures is also associated with other forms of measurement error, one example of which can be estimated via Kriging—a spatial interpolation method that predicts exposures and their prediction variances at unmonitored

residential locations [46]. A related form of uncertainty is that due to correlation between co-pollutants and PM chemical components measured with error.

A unified statistical framework that can effectively extend conceptually simple analyses by incorporating the effect of diagnostic insensitivity as well as correlated exposures and measurement errors is therefore needed [47, 48]. A fully Bayesian hierarchical framework in which site-specific regression parameters are represented as random effects with prior distributions reflecting anticipated variation among sites meets this need [49]. The advantage of this framework is that uncertainty in exposure measurements can be represented within it by prior distributions derived from the above-referenced participant address geocoding analyses, kriging analyses, and random-effects meta-analyses of the bivariate association between personal and ambient pollution concentrations [41-44, 46]. Additional sources of uncertainty—namely those associated with co-pollutants and PM chemical components—can be incorporated in a similar manner.

Modeling efforts of this nature would be misleading if factors associated with the ambient-personal correlation were to differ substantially among participants and the studies in which they are enrolled. They also would be of questionable utility if the studies on which they are based were unable to provide the spatiotemporal variation in exposures absent in available cross-sectional examinations of single-city populations. Future studies would therefore benefit from being geographically diverse, longitudinally designed, and open to trans-disciplinary, cross-study collaboration, the facilitation of which is a goal of e.g. the PhenX Project [50]. Future studies would also benefit from being gender, race and health inclusive such that comparisons of air pollution-AF associations across subpopulations are possible. This is an especially important issue from the regulatory perspective, which is concerned with the identification of subpopulations susceptible to the adverse effects of ambient air pollution so that population-wide pollution control strategies with an adequate margin of safety can be devised, regardless of whether susceptibility is acquired or innate [51, 52].

To this end, availability of single nucleotide polymorphisms typed on genome-wide arrays would allow researchers to investigate interactions between relevant, but previously unconsidered genetic and environmental exposures in studies of AF and its ECG predictors. The value of such studies is usually viewed in terms of their promise for improved understanding of pathophysiological mechanisms underlying genetic and environmental susceptibility—insight that has not been provided by published genome-wide association studies of AF [10-13]. However, this view overlooks the potential public health and regulatory importance of gene-environment interactions in the study of air pollution-AF associations [53]. The size of genetically susceptible populations as well as the likelihood and severity of the adverse PM effects they experience are both pertinent in this regard.

To further increase their pertinence and regulatory utility, effects of population-wide reductions in air pollution concentrations on AF can be estimated using epidemiologic measures of population burden. Such measures might include expected proportional changes in the exposure-weighted relative risks associated with shifts in exposure distributions accompanying a range of potential changes in regulatory standards and numbers of participants with exposures above a given regulatory standard among whom one excess case

of AF can be attributed to exposure [54, 55]. Collectively, the measures would be capable of providing quantitative insight into the proportion of exposure-attributable AF that could be reduced by establishing and complying with stricter standards.

## Summary

Studies examining the environmental epidemiology of atrial arrhythmogenesis have begun to provide insight into the epidemiology of atrial fibrillation. However, a research agenda focused on reducing uncertainty in outcomes and exposures; distinguishing effects of pervasive and correlated environmental exposures; evaluating susceptibility factors in subpopulations defined by sociodemographic, clinical and genetic characteristics; and informing regulatory policies in large, ethnically and geographically diverse, clinically well-characterized populations is needed. These investments have the capacity to increase our understanding of the pathophysiological mechanisms underlying atrial fibrillation and its clinical sequelae, inform environmental policy, and in doing so, improve public health.

## Acknowledgments

Preparation of this paper was supported in part by grants R01-ES012238 and T32-HL007055 from the National Institute of Environmental Health Sciences (NIEHS) and National Heart, Lung and Blood Institute (NHLBI). The conclusions presented herein are those of the authors and do not necessarily represent those of the NIEHS or NHLBI.

## References

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001; 285:2370–5. [PubMed: 11343485]
2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J*. 2006; 27:949–53. [PubMed: 16527828]
3. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. *Heart*. 2001; 86:284–8. [PubMed: 11514479]
4. Soliman EZ, Prineas RJ, Case LD, et al. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. *Stroke*. 2009; 40:1204–11. [PubMed: 19213946]
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994; 154:1449–57. No authors listed. [PubMed: 8018000]
6. Roy D, Talajic M, Dubuc M, et al. Atrial fibrillation and congestive heart failure. *Curr Opin Cardiol*. 2009; 24:29–34. [PubMed: 19102036]
7. Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. *Circulation*. 2009; 119:606–18. [PubMed: 19188521]
8. Ellinor PT, Yoerger DM, Ruskin JN, et al. Familial aggregation in lone atrial fibrillation. *Hum Genet*. 2005; 118:179–84. [PubMed: 16133178]
9. Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. *JAMA*. 2004; 291:2851–5. [PubMed: 15199036]
10. Gudbjartsson DF, Arnar DO, Helgadóttir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature*. 2007; 448:353–7. [PubMed: 17603472]
11. Gudbjartsson DF, Holm H, Gretarsdóttir S, et al. A sequence variant in ZFX3 on 16q22 associates with atrial fibrillation and ischemic stroke. *Nat Genet*. 2009; 41:876–8. [PubMed: 19597491]

12. Ellinor PT, Lunetta KL, Glazer NL, et al. Common variants in KCNN3 are associated with lone atrial fibrillation. *Nat Genet.* 2010; 42:240–4. [PubMed: 20173747]
13. Benjamin EJ, Rice KM, Arking DE, et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. *Nat Genet.* 2009; 41:879–81. [PubMed: 19597492]
14. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J.* 2009; 158:111–7. [PubMed: 19540400]
15. Brook RD, Franklin B, Cascio W, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the American Heart Association. *Circulation.* 2004; 109:2655–71. [PubMed: 15173049]
16. United States Environmental Protection Agency. U.S. EPA, Washington, DC: 2009. Integrated Science Assessment for Particulate Matter (Final Report). EPA/600/R-08/139F. Available at: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
17. Geiser M, Rothen-Rutishauser B, Kapp N, et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. *Environ Health Perspect.* 2005; 113:1555–60. [PubMed: 16263511]
18. Nemmar A, Hoet PH, Vanquickenborne B, et al. Passage of inhaled particles into the blood circulation in humans. *Circulation.* 2002; 105:411–4. [PubMed: 11815420]
19. Wallenborn JG, Schladweiler MJ, Richards JH, et al. Differential pulmonary and cardiac effects of pulmonary exposure to a panel of particulate matter-associated metals. *Toxicol Appl Pharmacol.* 2009; 241:71–80. [PubMed: 19679144]
20. Beharier O, Etzion Y, Levi S, et al. The involvement of ZnT-1, a new modulator of cardiac L-type calcium channels, in remodeling atrial tachycardia. *Ann N Y Acad Sci.* 2010; 1188:87–95. [PubMed: 20201890]
21. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. *Circulation.* 2002; 105:2753–9. [PubMed: 12057990]
22. Singh JP, Larson MG, Levy D, et al. Is baseline autonomic tone associated with new onset atrial fibrillation?: Insights from the framingham heart study. *Ann Noninvasive Electrocardiol.* 2004; 9:215–20. [PubMed: 15245336]
23. Whitsel EA, Quibrera PM, Christ SL, et al. Heart rate variability, ambient particulate matter air pollution and glucose homeostasis: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative. *Am J Epidemiol.* 2009; 169:693–703. [PubMed: 19208727]
24. Mills NL, Tornqvist H, Gonzalez MC, et al. Ischemic and thrombotic effects of dilute diesel-exhaust inhalation in men with coronary heart disease. *N Engl J Med.* 2007; 357:1075–82. [PubMed: 17855668]
25. United States Environmental Protection Agency. Possible pathways / modes of action. U.S. EPA, Washington, DC: 2009. Integrated Science Assessment for Particulate Matter (Final Report). Chapter 5EPA/600/R-08/139F. Available at: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
26. Zhang Z, Whitsel EA, Quibrera PM, et al. Short-term exposure to ambient fine particulate matter and electrocardiographic measures of myocardial ischemia in women: The Environmental Epidemiology of Arrhythmogenesis in the Women's Health Initiative. *Environ Health Perspect.* 2009; 117:571–756.
27. Berger A, Zareba W, Schneider A, et al. Runs of ventricular and supraventricular tachycardia triggered by air pollution in patients with coronary heart disease. *J Occup Environ Med.* 2006; 48:1149–58. [PubMed: 17099451]
28. Dockery DW, Luttmann-Gibson H, Rich DQ, et al. Association of air pollution with increased incidence of ventricular tachyarrhythmias recorded by implanted cardioverter defibrillators. *Environ Health Perspect.* 2005; 113:670–4. [PubMed: 15929887]
29. Dockery DW, Luttmann-Gibson H, Rich DQ, et al. Particulate air pollution and nonfatal cardiac events. Part II. Association of air pollution with confirmed arrhythmias recorded by implanted defibrillators. *Res Rep Health Eff Inst.* 2005:83–126. discussion 7-48. [PubMed: 17153518]
30. Ebelt ST, Wilson WE, Brauer M. Exposure to ambient and nonambient components of particulate matter: a comparison of health effects. *Epidemiology.* 2005; 16:396–405. [PubMed: 15824557]



31. Metzger KB, Klein M, Flanders WD, et al. Ambient air pollution and cardiac arrhythmias in patients with implantable defibrillators. *Epidemiology*. 2007; 18:585–92. [PubMed: 17700247]
32. Peters A, Liu E, Verrier RL, et al. Air pollution and incidence of cardiac arrhythmia. *Epidemiology*. 2000; 11:11–7. [PubMed: 10615837]
33. Pope CA 3rd, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. *Circulation*. 2004; 109:71–7. [PubMed: 14676145]
34. Rich DQ, Kim MH, Turner JR, et al. Association of ventricular arrhythmias detected by implantable cardioverter defibrillator and ambient air pollutants in the St Louis, Missouri metropolitan area. *Occup Environ Med*. 2006; 63:591–6. [PubMed: 16698809]
35. Rich DQ, Mittleman MA, Link MS, et al. Increased risk of paroxysmal atrial fibrillation episodes associated with acute increases in ambient air pollution. *Environ Health Perspect*. 2006; 114:120–3. [PubMed: 16393668]
36. Rich DQ, Schwartz J, Mittleman MA, et al. Association of short-term ambient air pollution concentrations and ventricular arrhythmias. *Am J Epidemiol*. 2005; 161:1123–32. [PubMed: 15937021]
37. Rich KE, Petkau J, Vedal S, et al. A case-crossover analysis of particulate air pollution and cardiac arrhythmia in patients with implantable cardioverter defibrillators. *Inhal Toxicol*. 2004; 16:363–72. [PubMed: 15204752]
38. Sarnat SE, Suh HH, Coull BA, et al. Ambient particulate air pollution and cardiac arrhythmia in a panel of older adults in Steubenville, Ohio. *Occup Environ Med*. 2006; 63:700–6. [PubMed: 16757505]
39. Vedal S, Rich K, Brauer M, et al. Air pollution and cardiac arrhythmias in patients with implantable cardioverter defibrillators. *Inhal Toxicol*. 2004; 16:353–62. [PubMed: 15204751]
40. Liao D, Whitsel EA, Duan Y, et al. Ambient particulate air pollution and ectopy--the environmental epidemiology of arrhythmogenesis in Women's Health Initiative Study, 1999-2004. *J Toxicol Environ Health A*. 2009; 72:30–8. [PubMed: 18979352]
41. Whitsel EA, Quibrera PM, Smith RL, et al. Accuracy of commercial geocoding: assessment and implications. *Epidemiol Perspect Innov*. 2006; 3:8. [PubMed: 16857050]
42. Whitsel EA, Rose KM, Wood JL, et al. Accuracy and repeatability of commercial geocoding. *Am J Epidemiol*. 2004; 160:1023–9. [PubMed: 15522859]
43. Avery CL, Mills KT, Williams R, et al. Estimating error in using Ambient PM2.5 concentrations as proxies for personal exposures: a review. *Epidemiology*. 2010; 21:215–23. [PubMed: 20087191]
44. Avery, CL., Mills, KT., Williams, R., et al. Estimating Error in Using Residential Outdoor PM2.5 Concentrations as Proxies for Personal Exposures: a Meta-Analysis. *Environ Health Perspect*. 2010. <http://dx.doi.org/10.1289/ehp.0901158>
45. Williams R, Rea A, Vette A, et al. The design and field implementation of the Detroit Exposure and Aerosol Research Study. *J Expo Sci Environ Epidemiol*. 2009; 19:643–59. [PubMed: 18941480]
46. Liao D, Pequet DJ, Duan Y, et al. GIS approaches for the estimation of residential-level ambient PM concentrations. *Environ Health Perspect*. 2006; 114:1374–80. [PubMed: 16966091]
47. Phillips CV. Quantifying and reporting uncertainty from systematic errors. *Epidemiology*. 2003; 14:459–66. [PubMed: 12843772]
48. Rothman, KJ., Greenland, S. *Modern Epidemiology*. Philadelphia: Lippincott Williams & Wilkins; 1998.
49. Crooks JL, Whitsel EA, Quibrera PM, et al. The effect of ignoring interpolation error on the inferred relationship between ambient particulate matter exposure and median RR interval in post-menopausal women. *Epidemiology*. 2008; 19:S127.
50. PhenX. Consensus measures for phenotypes and exposures. 2010
51. United States Environmental Protection Agency. Clean Air Act. 2009
52. United States Environmental Protection Agency. Integrated Science Assessment for Particulate Matter (Final Report). U.S. EPA, Washington, DC: 2009. Chapter 1 Introduction EPA/600/R-08/139F. Available at: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>

53. Susceptible Subpopulations. U.S. EPA, Washington, DC: 2009. Integrated Science Assessment for Particulate Matter (Final Report). United States Environmental Protection Agency Chapter 8 EPA/600/R-08/139F. Available at: <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=216546>
54. Bender R, Kuss O, Hildebrandt M, et al. Estimating adjusted NNT measures in logistic regression analysis. *Stat Med.* 2007; 26:5586–95. [PubMed: 17879268]
55. Murray CJ, Ezzati M, Lopez AD, et al. Comparative quantification of health risks conceptual framework and methodological issues. *Popul Health Metr.* 2003; 1:1. [PubMed: 12780936]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript